ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an inve… Read more
ContraFect Corporation (CFRXQ) - Net Assets
Latest net assets as of September 2023: $-5.76 Million USD
Based on the latest financial reports, ContraFect Corporation (CFRXQ) has net assets worth $-5.76 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.12 Million) and total liabilities ($14.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.76 Million |
| % of Total Assets | -63.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | -313.86% |
| 10-Year Change | N/A |
| Growth Volatility | 145.96 |
ContraFect Corporation - Net Assets Trend (2016–2022)
This chart illustrates how ContraFect Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ContraFect Corporation (2016–2022)
The table below shows the annual net assets of ContraFect Corporation from 2016 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-09-30 | $-11.85 Million | -124.00% |
| 2021-09-30 | $49.38 Million | +291.26% |
| 2020-09-30 | $12.62 Million | -18.82% |
| 2019-09-30 | $15.54 Million | +180.49% |
| 2018-09-30 | $5.54 Million | -82.23% |
| 2017-09-30 | $31.19 Million | +59.86% |
| 2016-09-30 | $19.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ContraFect Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17958719000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-32.00K | % |
| Other Components | $313.88 Million | % |
| Total Equity | $-11.85 Million | 100.00% |
ContraFect Corporation Competitors by Market Cap
The table below lists competitors of ContraFect Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FIRST CLASS MET. LS-001
F:WN9
|
$107.26 |
|
Fruitas Holdings Inc
PSE:FRUIT
|
$107.57 |
|
Digital Media Solutions Inc.
OTCQB:DMSL
|
$107.62 |
|
QUIZ PLC
LSE:QUIZ
|
$108.07 |
|
Pembroke VCT PLC
LSE:PEMB
|
$106.93 |
|
Tenon Medical, Inc. Warrant
NASDAQ:TNONW
|
$106.65 |
|
Giza General Contracting
EGX:GGCC
|
$106.21 |
|
NAIROBI BUSINESS VENTURES LTD
XNAI:NBVL
|
$106.02 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ContraFect Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 49,376,000 to -11,852,000, a change of -61,228,000 (-124.0%).
- Net loss of 65,153,000 reduced equity.
- New share issuances of 6,995,000 increased equity.
- Other comprehensive income increased equity by 52,000.
- Other factors decreased equity by 3,122,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-65.15 Million | -549.72% |
| Share Issuances | $7.00 Million | +59.02% |
| Other Comprehensive Income | $52.00K | +0.44% |
| Other Changes | $-3.12 Million | -26.34% |
| Total Change | $- | -124.00% |
Book Value vs Market Value Analysis
This analysis compares ContraFect Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-09-30 | $465.43 | $0.00 | x |
| 2017-09-30 | $448.87 | $0.00 | x |
| 2018-09-30 | $58.29 | $0.00 | x |
| 2019-09-30 | $150.13 | $0.00 | x |
| 2020-09-30 | $44.35 | $0.00 | x |
| 2021-09-30 | $107.41 | $0.00 | x |
| 2022-09-30 | $-22.73 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ContraFect Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-174.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -146.25% | 0.00% | 0.00x | 1.93x | $-30.49 Million |
| 2017 | -49.75% | 0.00% | 0.00x | 1.61x | $-18.64 Million |
| 2018 | -679.98% | 0.00% | 0.00x | 5.93x | $-38.24 Million |
| 2019 | -82.31% | 0.00% | 0.00x | 2.25x | $-14.35 Million |
| 2020 | -223.11% | 0.00% | 0.00x | 4.05x | $-29.42 Million |
| 2021 | -41.08% | 0.00% | 0.00x | 1.35x | $-25.22 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-63.97 Million |
Industry Comparison
This section compares ContraFect Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ContraFect Corporation (CFRXQ) | $-5.76 Million | -146.25% | N/A | $107.00 |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |